Tumor Necrosis Factor Blocker [EPC]

717522 reported adverse events

Drugs of this class: ETANERCEPT GOLIMUMAB INFLIXIMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	76273
1	INJECTION SITE PAIN	56163
2	ARTHRALGIA	42841
3	INJECTION SITE ERYTHEMA	41013
4	RHEUMATOID ARTHRITIS	37477
5	PAIN	36872
6	FATIGUE	26943
7	OFF LABEL USE	26710
8	PSORIASIS	26022
9	PAIN IN EXTREMITY	24681

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	INJECTION SITE RECALL REACTION	481	0.9816
1	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	264	0.9742
2	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1236	0.8374
3	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	600	0.8253
4	RHEUMATOID FACTOR POSITIVE	1054	0.7937
5	C-REACTIVE PROTEIN ABNORMAL	1892	0.7857
6	INJECTION SITE MACULE	466	0.7397
7	INJECTION SITE WARMTH	10365	0.6482
8	SYNOVITIS	4735	0.6400
9	JOINT DESTRUCTION	607	0.5986

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]